Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + capecitabine + bevacizumab as second-line therapy for advanced colorectal cancer
ChiCTR2500104823Phase 2Not yet recruiting
- Sponsor
- Heze Municipal Hospital
- Start
- Jun 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in colorectal cancer (CRC), sponsored by Heze Municipal Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500104823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104823.